The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. Insights From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) Trial.

JACC: Heart Failure

Volumn 1, Issue 6, 2013, Pages 488-496

  Greene, Stephen J ^a   Vaduganathan, Muthiah ^b   Wilcox, Jane E ^a   Harinstein, Matthew E ^c   Maggioni, Aldo P ^d   Subacius, Haris ^a   Zannad, Faiez ^e   Konstam, Marvin A ^f   Chioncel, Ovidiu ^g   Yancy, Clyde W ^a   Swedberg, Karl ^h   Butler, Javed ⁱ   Bonow, Robert O ^a   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d ANMCO RESEARCH CENTER   (Italy)

^e UNIVERSITÉ DE LORRAINE   (France)

^f TUFTS MEDICAL CENTER   (United States)

^g Inst Cardiovasc Dis CC Iliescu   (ROM)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Heart rate; Hospitalization; Mortality; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PLACEBO; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ADULT; AGE DISTRIBUTION; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS RHYTHM; SURVIVAL RATE; CLINICAL TRIAL; EPIDEMIOLOGY; HEART STROKE VOLUME; HOSPITALIZATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA;

AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; EPIDEMIOLOGIC METHODS; FEMALE; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMANS; MALE; PROGNOSIS; STROKE VOLUME;

EID: 84889060227     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.08.005     Document Type: Article

References (26)

1. Bohm M., Swedberg K., Komajda M., et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010, 376:886-894.
2. Reil J.C., Custodis F., Swedberg K., et al. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 2011, 100:11-19.
3. Pocock S.J., Wang D., Pfeffer M.A., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006, 27:65-75.
4. Poole-Wilson P.A., Uretsky B.F., Thygesen K., Cleland J.G., Massie B.M., Ryden L. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003, 89:42-48.
5. Metra M., Torp-Pedersen C., Swedberg K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005, 26:2259-2268.
6. McAlister F.A., Wiebe N., Ezekowitz J.A., Leung A.A., Armstrong P.W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009, 150:784-794.
7. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:807-816.
8. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
9. Gheorghiade M., Orlandi C., Burnett J.C., et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). JCard Fail 2005, 11:260-269.
10. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297:1319-1331.
11. Gheorghiade M., Konstam M.A., Burnett J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297:1332-1343.
12. Castagno D., Skali H., Takeuchi M., et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. JAm Coll Cardiol 2012, 59:1785-1795.
13. Bui A.L., Grau-Sepulveda M.V., Hernandez A.F., et al. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J 2013, 165:567-574.e6.
14. O'Connor C.M., Abraham W.T., Albert N.M., et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008, 156:662-673.
15. Lechat P., Hulot J.S., Escolano S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001, 103:1428-1433.
16. Conway M.A., Allis J., Ouwerkerk R., Niioka T., Rajagopalan B., Radda G.K. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991, 338:973-976.
17. Colin P., Ghaleh B., Monnet X., Hittinger L., Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. JPharmacol Exp Ther 2004, 308:236-240.
18. Reil J.C., Reil G.H., Bohm M. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. Trends Cardiovasc Med 2009, 19:152-157.
19. Thackray S.D., Ghosh J.M., Wright G.A., et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006, 152:713.e9-713.e13.
20. Swedberg K., Viquerat C., Rouleau J.L., et al. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 1984, 54:783-786.
21. Abraham W.T., Fonarow G.C., Albert N.M., et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). JAm Coll Cardiol 2008, 52:347-356.
22. Gheorghiade M., Pang P.S., Ambrosy A.P., et al. Acomprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev 2012, 17:485-509.
23. Swedberg K., Komajda M., Bohm M., et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings From the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JAm Coll Cardiol 2012, 59:1938-1945.
24. Mebazaa A., Pang P.S., Tavares M., et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010, 31:832-841.
25. Gheorghiade M., Ruschitzka F. Beyond dyspnoea as an endpoint in acute heart failure trials. Eur Heart J 2011, 32:1442-1445.
26. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006, 296:2217-2226.